Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709947 | 1.00 | CA1 (0.35) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL17920111 | 1.00 | CA1 (0.35) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL19955121 | 0.90 | KDM4C (0.40) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL15187247 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL17920012 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL17920016 | 0.85 | MMP9 (0.32) | — | |
| SCHEMBL25919388 | 0.84 | GAA (0.31) | — | |
| SCHEMBL16022889 | 0.81 | ALDH1A1 (0.46) | KDM4CKDM4APHF8CHRNB2CHRNA4 | |
| SCHEMBL20880284 | 0.81 | CA1 (0.32) | CA1 | |
| SCHEMBL16360268 | 0.79 | CA1 (0.38) | CA1KDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10993944-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20210038601-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | Aneira Pharma, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2018-04-05 | — | — | US | disclosed |
| EP-2627664-B1 | CYCLOSPORIN ANALOGS | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2627663-B1 | CYCLOSPORIN ANALOGS | ALLERGAN INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
| EP-2376524-B1 | DERIVATIVES OF CYCLOSPORIN A | CYPRALIS LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| EP-2646043-B1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9561259-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8648048-B2 | Methods of providing therapeutic effects using cyclosporin components | ALLERGAN, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8633162-B2 | Methods of providing therapeutic effects using cyclosporin components | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130156713-A1 | COMPOSITIONS FOR ENHANCING NAIL HEALTH | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130136707-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013028615-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | S&T GOLBAL INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012075494-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012021796-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012009715-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | CA1 1405/4885KDM4C 3849/4885KDM4A 3906/4885 |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | CA1 2159/4885KDM4C 4602/4885KDM4A 4565/4885 |
| US-20130156713-A1 | COMPOSITIONS FOR ENHANCING NAIL HEALTH | TYR, NACA, PIK3C3 | CA1 4647/4885KDM4C 361/4885KDM4A 679/4885 |
| US-20130136707-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | TYR, NACA, PIK3C3 | CA1 4685/4885KDM4C 481/4885KDM4A 833/4885 |
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | ADM2, SLC7A1, ARG1 | CA1 2766/4885KDM4C 1718/4885KDM4A 2288/4885 |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | CYP21A2, CHP1, CYP51A1 | CA1 1241/4885KDM4C 3442/4885KDM4A 2886/4885 |
| US-10993944-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | CA1 1534/4885KDM4C 844/4885KDM4A 1470/4885 |
| US-20210038601-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | COXFA4L2, UNG, TYR | CA1 1534/4885KDM4C 844/4885KDM4A 1470/4885 |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | CA1 2992/4885KDM4C 2915/4885KDM4A 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.